-
Summary of latest advances in non-small cell lung cancer, MET-positive targeted treatment
Time of Update: 2020-06-16
2020ASCO series small cell lung cancer, immuno-targeted treatment latest progress summary non-small cell lung cancer, targeted treatment latest progress summary non-small cell lung cancer, MET-positi
-
Thyroid: Metabolic Syndrome and Risk of Thyroid Cancer
Time of Update: 2020-06-16
The relationship between metabolic syndrome and its components and the risk of thyroid cancer is not clear In a recent study published in the authoritative journal Thyroid, researchers conducted a la
-
Lancet oncol: ARIEL3 trial: An exploratory analysis of Rucaparib's maintenance treatment for platinum-sensitive recurrent ovarian cancer more than 2 years later
Time of Update: 2020-06-16
In the ARIEL3 trial (evaluating parP inhibitor rucaparib for recurrent ovarian cancer), rucaparib maintenance therapy significantly improved the patient's progression-free survival compared to placeb
-
Lancet oncol: Tafasitamab combined to the efficacy of nadoamine treatment for relapse/refractive diffuse large B cell lymphoma
Time of Update: 2020-06-16
Relapsed or refractive diffuse large B-cell lymphoma is not suitable for patients with self-contained stem cell transplantation with poor prognosis and few treatment options Tafasitamab (MOR208) is a
-
Lancet: Atezolizumab-Vemurafenib-Cobimetinib first-line treatment for advanced BRAF V600 mutant positive melanoma
Time of Update: 2020-06-16
The IMspire150 study, which aims to evaluate the treatment of BRAF, MEK inhibitors and combined immunocheckpoint inhibitors for braF V600 mutant-positive late-stage or metastatic melanoma, was recent
-
Blood: Does the interval between diagnosis and the start of treatment affect the prognosis of newly diagnosed AML patients?
Time of Update: 2020-06-16
Since the prognosis of acute leukemia without treatment is poor, it is recommended that patients with newly diagnosed acute myeloid leukemia (AML) begin treatment immediately In a new article publish
-
NICE UK approves Roche's PD-L1 single anti-Tecentriq treatment for triple-negative breast cancer after offering big discount
Time of Update: 2020-06-16
The National Institute of Health and Clinical Excellence (NICE) has approved its immunotherapy PD-L1 monoantiticriq (atezolizumab) for the treatment of triple-negative breast cancer (TNBC) patients a
-
First-line immunotherapy for bladder cancer! Merck/Pfizer Bavencio Maintenance Therapy Phase III clinically significantly superior to standard care, extending patient survival!
Time of Update: 2020-06-16
JUNE 11, 2020 /PRNewswire/ -- Pfizer and partner Merck KGaA have announced the total survival results of the phase-by-phase analysis of the anti-PD-L1 therapy Bavencio (avelumab) first-line maintenanc
-
Nature: Key Targets for Neutrophils To Promote Breast Cancer Metastasis Found - CCDC25
Time of Update: 2020-06-16
Neutrophils are immune cells that provide the body with the first line of defense against infection However, in many cases, neutrophils also have the ability to promote cell cell metastasis In a new
-
ASCO 2020 Oichtini strength can not be underestimated! 2-year DFS rate of EGFRm non-small cell lung cancer reaches 89%
Time of Update: 2020-06-16
The 2020 annual meeting of the American Society of Clinical Oncology (ASCO) has been successfully concluded, and this academic feast has been a wonderful event that has won the attention of oncologis
-
Blood: A small number of T-cells that identify tumor-related antigens stimulate antitumor response
Time of Update: 2020-06-16
Tumor-related antigen (TAA) is a monomorphic self-antigen that is considered an immunotherapy target for malignant tumors Is it possible to find T-cells with sufficient affinity in the T-cell pool of
-
Blood: JAK/STAT signal suppression enhances the sensitivity of CD8 T cells to dexamethasone-induced apoptosis
Time of Update: 2020-06-16
Cytokine storm syndrome (CSS) is a severe hyper-inflammatory state characterized by overactivation of the immune system, which can lead to organ damage and patient death Phytopha lymphatic tissue cyt
-
Lancet oncol: Clinical characteristics and risk factors for cancer patients infected with the new coronavirus in Wuhan
Time of Update: 2020-06-16
COVID-19 has spread around the world Cancer patients are reported to be epidemiologically sensitive to the new coronavirus The purpose of this study is to systematically describe the clinical charact
-
Take stock: A selection of Blood Research Highlights of June 11, 2020
Time of Update: 2020-06-16
Transcription factor ATF4 activation BCL11A transcription to silent fetal hemoglobin expression Fetal hemoglobin reactivation remains a critical goal for the treatment of patients with sickle cell di
-
NMPA: Amjin company's land Shudan resistance in the domestic conditional approval
Time of Update: 2020-06-16
According to official information released by the State Drug Administration, the application for import registration of the dissudan anti-injection injection developed by Amgen Corporation (AMGN.US)
-
Lancet oncol: Mortality after breast malignancy infection with COVID-19
Time of Update: 2020-06-16
Early reports of COVID-19 cancer patients suggest that cancer patients with COVID-19 had a higher mortality rate than the general population Given the age of patients with chest cancer, smoking habit
-
Blood: Talin1 is the main Rap1 effector for platelet integration activation
Time of Update: 2020-06-16
Rap1 is the main convergence point of platelet signaling pathway, regulating the combination of talin1 and integrated b cytoplasmic domain, thus activating the integrated hormone, promoting platelet
-
1 case of imaging performance of adrenal melanoma
Time of Update: 2020-06-16
The case of the male, 49 years old, a medical examination found that the right adrenal area of the swelling, had a history of fainting Deny the history of chronic diseases such as "hypertension, coro
-
A selection of Lancet research highlights on June 13, 2020
Time of Update: 2020-06-16
1 An important method for seropositive seropositive rates of new coronal pneumonia in the Geneva population in Geneva, Switzerland, to assess the prevalence of SARS-CoV prevalence in the Swiss popula
-
Breast Cancer Treat: Palbociclib Calais as estrogen receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer treatment effects
Time of Update: 2020-06-16
In the initial PALOMA-2 (NCT01740427) analysis, the median follow-up was 23 months, and palbociclib calais can significantly prolong estrogen receptor-positive (ER-plus)/human epidermal growth factor